© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 81508 refers to a specific laboratory test that assesses the risk of fetal congenital abnormalities through biochemical assays of two proteins found in maternal serum. This test measures the levels of pregnancy-associated plasma protein A (PAPP-A) and human chorionic gonadotropin (hCG) in the blood of pregnant individuals. The primary purpose of this test is to evaluate the risk for certain chromosomal abnormalities, notably trisomy 18 and trisomy 21, which is commonly known as Down syndrome. The test is most effective when conducted during a specific window of gestation, particularly between 10 weeks and 3 days to 13 weeks and 6 days. During this period, the sensitivity of the test results is maximized, allowing for a more accurate risk assessment. The blood sample required for this test is obtained through a procedure known as venipuncture, which is separately reportable. The serum collected is then analyzed using a quantitative chemiluminescent immunoassay, a sophisticated laboratory technique that quantifies the proteins in the sample to generate a risk score. This score is crucial for healthcare providers in making informed decisions regarding further diagnostic testing or monitoring during the pregnancy.
© Copyright 2025 Coding Ahead. All rights reserved.
The CPT® Code 81508 is indicated for use in the following scenarios:
The procedure for CPT® Code 81508 involves several key steps that ensure accurate measurement of the proteins in maternal serum:
After the procedure associated with CPT® Code 81508, patients may be advised to follow up with their healthcare provider to discuss the results of the test. Depending on the risk score obtained, further diagnostic testing may be recommended to confirm or rule out any potential abnormalities. Patients should also be informed about any signs or symptoms to monitor during their pregnancy and encouraged to maintain regular prenatal care appointments for ongoing assessment and support.
| Short Descr | FTL CGEN ABNOR TWO PROTEINS | Medium Descr | FETAL CONGENITAL ABNOR ASSAY TWO PROTEINS | Long Descr | Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 234 - Pathology |
| XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GW | Service not related to the hospice patient's terminal condition |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2013-01-01 | Added | Added |